Department of Oncology, Linyi People's Hospital, Linyi, Shandong 276000, China.
Department of Comprehensive Intervention, Linyi People's Hospital, Linyi, Shandong 276000, China.
Int Immunopharmacol. 2020 Jun;83:106481. doi: 10.1016/j.intimp.2020.106481. Epub 2020 Apr 24.
Programmed death ligand 1 (PD-L1) has been reported to be connected to prognosis in individuals with malignant pleural mesothelioma (MPM), although there is no consensus based on data from previous studies. Accordingly, this quantitative meta-analysis investigated prognostic and clinicopathological utility of PD-L1 in patients with MPM.
A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Library databases for articles published up to October 4, 2019 was performed. Studies using immunohistochemical techniques to detect/quantify the expression of PD-L1 in MPM tissue were enrolled in the analysis. The combined hazard ratio (HR) and corresponding 95% confidence interval (CI) was applied to assess the association between PD-L1 expression and overall survival (OS).
A total of 11 studies comprising 1606 patients was included in the present meta-analysis. For OS, pooled data revealed an HR of 1.50 (95% CI 1.32-1.70; p < 0.001), suggesting that patients with PD-L1 overexpression experience inferior OS. Subgroup analysis revealed that elevated PD-L1 remained a significant prognostic indicator for worse OS, irrespective of sample size, cut-off value, ethnicity, and Newcastle-Ottawa Scale score. Moreover, PD-L1 overexpression was associated with non-epithelioid histology (odds ratio 4.30 [95% CI 1.89-9.74]; p < 0.001).
Results of this meta-analysis show that elevated expression of PD-L1 could be a factor predicting poorer survival in patients with MPM.
程序性死亡配体 1（PD-L1）已被报道与恶性胸膜间皮瘤（MPM）患者的预后相关，但基于以往研究的数据尚无共识。因此，本定量荟萃分析旨在研究 PD-L1 在 MPM 患者中的预后和临床病理应用价值。
对 PubMed、Web of Science、Embase 和 Cochrane Library 数据库进行了全面检索，以获取截至 2019 年 10 月 4 日发表的文章。分析中纳入了使用免疫组织化学技术检测/定量 MPM 组织中 PD-L1 表达的研究。采用合并风险比（HR）和相应的 95%置信区间（CI）来评估 PD-L1 表达与总生存期（OS）之间的关联。
本荟萃分析共纳入 11 项研究，包含 1606 例患者。对于 OS，汇总数据显示 HR 为 1.50（95%CI 1.32-1.70；p<0.001），表明 PD-L1 过表达的患者 OS 较差。亚组分析表明，不论样本量、截断值、种族和纽卡斯尔-渥太华量表评分如何，升高的 PD-L1 仍然是 OS 预后不良的显著预测指标。此外，PD-L1 过表达与非上皮样组织学相关（比值比 4.30 [95%CI 1.89-9.74]；p<0.001）。
本荟萃分析结果表明，PD-L1 表达升高可能是预测 MPM 患者生存较差的一个因素。
